DARANIDE
LOE Approachingdichlorphenamide
NDAORALTABLET
Approved
Jul 1958
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
DARANIDE (dichlorphenamide) is carbonic anhydrase inhibitors [moa]. Approved for primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, related variants ( ). First approved in 1958.
Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Daranide (dichlorphenamide) is an oral carbonic anhydrase inhibitor approved in 1958 for treating primary hyperkalemic and hypokalemic periodic paralysis. It reduces intraocular pressure and prevents paralytic episodes by inhibiting carbonic anhydrase, altering ion balance in affected tissues. The drug addresses a rare genetic disorder affecting muscle function.
LOE Approaching
Legacy product in late lifecycle with minimal linked job openings and declining strategic focus as market exclusivity erodes.
Mechanism of Action
Carbonic Anhydrase Inhibitors
Pharmacologic Class:
Carbonic Anhydrase Inhibitor
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.